Qiagen N.V. and BD (Becton, Dickinson and Company) announced that they have reached a settlement in the patent infringement lawsuit related to Qiagen’s NeuMoDx 96 and NeuMoDx 288 clinical PCR systems that Qiagen acquired from NeuMoDx in 2020.
Under terms of the agreement, all pending patent and non-patent claims have been resolved between BD and Qiagen and the co-defendants who were former officers of NeuMoDx in the lawsuit in the U.S. District Court for the District of Delaware. BD will receive a one-time, lump-sum payment of $53 million. The settlement includes general releases of all parties with no admissions of wrongdoing.
